TrialA Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Trial details
- Registry ID
- NCT07012395
- Phase
- Phase 2
Drug research
SPY003
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as SPY003-207
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative ColitisNCT07012395 | SYRE | Phase 2 | Recruiting | 2027-06Estimated |
| Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBDNCT07652294 | SYRE | Phase 2 | Enrolling by invitation | 2029-03-02Estimated |
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
Trial details
- Registry ID
- NCT07652294
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |